Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Iovance Biotherapeutics ( (IOVA) ).
On August 22, 2025, Iovance Biotherapeutics entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC for an at-the-market offering program. This agreement allows the company to issue and sell up to $350 million of its common stock, with Jefferies acting as the sales agent. The sale of shares will be conducted under a prospectus supplement to the company’s registration statement, and Jefferies will receive a commission of up to 3% on the gross sales proceeds. This strategic move could enhance Iovance’s financial flexibility and strengthen its market position.
The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Iovance Biotherapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by profitability and cash flow challenges. However, the positive sentiment from the earnings call and recent corporate events, including international expansion and strategic restructuring, provide a more optimistic outlook. Technical indicators suggest stabilization, but valuation concerns persist due to ongoing losses.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of novel cancer immunotherapies. The company’s primary products involve cell therapy treatments aimed at harnessing the power of a patient’s immune system to fight cancer.
Average Trading Volume: 17,157,304
Technical Sentiment Signal: Sell
Current Market Cap: $940.8M
For an in-depth examination of IOVA stock, go to TipRanks’ Overview page.